Purnima Tripathi

Background

About Purnima Tripathi

As a Therapy Access Manager at Novo Nordisk, I am on a mission to reshape the obesity market and establish obesity as a recognized therapy area in the South region of India. I take immense pride in being part of the only company pioneering the launch of anti-obesity medication in India, driving awareness, access, and adoption of evidence-based obesity treatments. With years of experience in Oncology, I was responsible for shaping market access and driving the success of innovative therapies. I was part of the historic launch launch of India’s first biosimilar monoclonal antibodies (MABs) with Viatris (Mylan), where I successfully established Bevacizumab as the No.1 brand in Delhi within a year and was recognized as the Best Performer Pan India-2019. My strong relationships with top oncologists have been a cornerstone of my success in this highly specialized field.I began my career in Oncology at Panacea Biotech, leading the efforts for India’s first biosimilar Nab-Paclitaxel, with a vision to shift prescribing habits from innovator to biosimilar therapies. By building strong relationships with leading oncologists and implementing strategic customer engagement, I contributed to market transformation in biosimilars.With an MBA in Marketing from Narsee Monjee Institute of Management Studies (NMIMS). I leverage my expertise in market development, strategic stakeholder engagement, and healthcare innovation to create lasting impact. I am always eager to learn new skills and explore new opportunities in the field of healthcare and marketing.